Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 25 Jan 2023
Price :
$35
*
At a glance
- Drugs Nalbuphine (Primary)
- Indications Prurigo nodularis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Trevi Therapeutics
- 12 Jan 2023 Results of population pharmacokinetic-pharmacodynamic model assessing efficacy of nalbuphine ER in patients with prurigo nodularis from two clinical trials (NCT02373215: 9 healthy subjects; NCT02174419: 62 subjects with PN), published in the British Journal of Clinical Pharmacology.
- 28 Mar 2022 Results of supplementary analyses assessing the psychometric properties of the Worst Itch Numeric Rating Scale, published in the Journal of the European Academy of Dermatology and Venereology
- 01 Mar 2022 Results published in the Journal of the European Academy of Dermatology and Venereology